Comend
Comend operates a two-sided SaaS marketplace that connects rare disease patient advocacy groups with researchers, CROs, and biopharma, offering free research coordination tools to PAGs and monetizing biopharma access to curated rare disease opportunities.
- Company typePrivate
- Founded2023
- HeadquartersToronto, Canada
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What Comend does
Comend Inc. is a Canadian SaaS company founded in 2023 and headquartered in Mississauga, Ontario, that operates a two-sided marketplace connecting rare disease patient advocacy groups (PAGs) with academic researchers, contract research organizations, consultants, and biopharmaceutical companies. Its core product is a web-based research platform built on Google Cloud infrastructure (with a signed Business Associate Agreement to support HIPAA compliance) that lets patient groups organize therapeutic research projects via Research Plan templates, manage pre-clinical toolkits containing biosamples, disease models, and clinical datasets, and broadcast Requests for Proposals (RFPs) to a curated list of academics and service providers. A separate Researcher Hub at researcher.comend.io provides academics, CROs, biotech, pharma, and consultants with profile creation and marketplace discovery, while a multi-tenant architecture enforces app isolation and per-organization access controls.
The platform's product surface is organized into five modules — Research Plans, Pre-clinical Toolkit, Requests for Proposals, Marketplace, and a dedicated Researcher Hub — and is augmented by Librarey, the founders' earlier rare-disease project, and a CRO marketplace layer added through a 2025 partnership with Odylia Therapeutics. Comend maintains OAuth 2.0 authentication, role-based access, encrypted data at rest and in transit, rate limiting, bot detection, and audit logging, with HIPAA-aligned readiness even though no protected health information is currently held.
Comend's commercial model is a freemium-plus-services construct: the core platform is provided free of charge to patient advocacy groups (the supply side, currently comprising 20+ foundations including The Rory Belle Foundation, AGSAA, CurePDE Foundation, PBD Project, Project 8p, and Odylia Therapeutics), while revenue is intended to be generated by helping biopharmaceutical companies identify and engage with rare disease research opportunities surfaced from the curated PAG ecosystem. Go-to-market relies on direct web self-service onboarding, organic social (LinkedIn, Instagram, X), and accelerator-driven enterprise introductions via PharmStars, under which Comend has met with multiple big pharma companies and received investment from the PharmStars fund. The company is privately held, has raised $765,000 from Character, Drive Capital, and PharmStars, and operates with a 1-10 person team plus an advisory bench spanning drug development and rare disease advocacy.
Comend firmographics
Firmographics- Name
- Comend
- Legal name
- Comend Inc.
- Website
- https://comend.io
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Comend operates a two-sided SaaS marketplace that connects rare disease patient advocacy groups with researchers, CROs, and biopharma, offering free research coordination tools to PAGs and monetizing biopharma access to curated rare disease opportunities.
- Ownership category
- akta.pro rank
Comend industry classification
Industry- Product category
- Research Collaboration Platform
- NAICS
- Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D) (HLAGAJAF)
- akta.pro secondary industry
- Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM)
Keywords
Where Comend is headquartered
LocationHeadquarters
- HQ city
- Toronto
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
Comend business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Biopharma Partnership Services: Comend generates revenue by helping biopharma companies identify opportunities in rare diseases. Patient groups use the free platform to organize and showcase their research, which Comend then surfaces to pharmaceutical companies seeking rare disease research opportunities.
- Platform Services for Patient Groups: The core platform is free for patient groups, serving as the supply side of the marketplace. Revenue is derived from the demand side (biopharma) accessing the curated patient group ecosystem.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Freemium | Others | Free for patient groups |
Distribution channels1 record
Marketing channels5 records
Comend product offering
Product offeringCore offering
Comend operates a two-sided SaaS marketplace that lets rare disease patient advocacy groups organize research plans, manage pre-clinical toolkits (biosamples, disease models, clinical datasets), and broadcast Requests for Proposals (RFPs) to researchers, CROs, and service providers. The platform also lets researchers, CROs, biotech, and pharma discover patient groups, research plans, biosamples, disease models, clinical datasets, and RFPs through a unified marketplace. Patient groups access all features for free, while Comend generates revenue by helping biopharma companies identify and evaluate rare disease research opportunities surfaced through the curated ecosystem.
Product overview
Comend operates as a unified research platform for genetic conditions, connecting patient groups with researchers to accelerate rare disease drug development. The core Comend Platform serves as the central hub, supplemented by specialized modules including Research Plans (for mapping therapeutic goals and projects), Pre-clinical Toolkit (for managing biosamples, disease models, and clinical datasets), Requests for Proposals (for broadcasting research opportunities), and the Marketplace (for discovering and connecting patient groups, tools, and partners). The platform also includes a dedicated Researcher Hub at researcher.comend.io for academic users. Additionally, Comend's creators developed Librarey as their first project in this space.
Differentiator
Problem solved
Functional benefit
Products and services
- Comend Platform The research platform for genetic conditions that connects patient groups with researchers, enabling discovery of projects, tools, and partners in one unified marketplace. Includes research plans, pre-clinical toolkit management, and RFP broadcasting capabilities.
- Comend Marketplace Central hub for browsing patient groups, biosamples, disease models, clinical datasets, research plans, and Requests for Proposals on the Comend platform. Serves researchers, CROs, biotech, pharma, and consultants seeking rare disease opportunities.
- Researcher Hub Researcher-facing portal at researcher.comend.io for completing profiles and accessing Comend's marketplace of research plans, biosamples, disease models, clinical datasets, and RFPs. Built for academics, CROs, biotech, pharma, and consultants.
Companies that use Comend
Customer profileNamed customers6 records
Segments3 records
Ideal customer profiles3 records
Comend technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- Yes
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Comend partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core and foundational.
- Odylia TherapeuticscoreComend partnered with Odylia to bring patient advocacy groups (PAGs) a marketplace of CROs and expanded research capabilities. Odylia is a nonprofit dedicated to accelerating treatments for rare diseases through gene therapy programs.
- LibrareyfoundationalLibrarey is credited as the creator of Comend. The platform is described as 'From the creators of Librarey', indicating Librarey is the parent project or founding team that developed Comend as their second venture in the rare disease research space.
Scale indicators1 record
Recent moves5 records
Expansion highlights5 records
Comend competitors and assessment
Company assessmentDirect peers
- TrialX: TrialX operates a patient recruitment and clinical trial matching platform connecting patients and researchers. It is the closest direct peer in matching rare disease and other patient populations to study opportunities, sharing Comend's core marketplace model.
- Antidote (formerly TrialReach): Antidote runs a patient recruitment marketplace for clinical trials, including rare disease populations. It competes head-to-head with Comend on the demand side — connecting biopharma and trial sponsors with engaged patient communities.
Broad incumbents
- Medable: Medable is a well-capitalized decentralized clinical trial technology platform serving pharma and CROs. While broader in scope than Comend, it increasingly pursues patient engagement workflows that overlap with Comend's research coordination vision.
- Veeva Systems: Veeva is a large incumbent life sciences cloud platform spanning clinical, regulatory, and commercial workflows. Its clinical operations suite addresses adjacent biopharma R&D needs and could plausibly extend into patient group coordination.
- IQVIA: IQVIA is the largest life sciences services and technology provider globally, with deep clinical trial and real-world data offerings. It is a broad incumbent that competes for the same biopharma R&D budgets Comend is targeting.
- Within3: Within3 provides a life sciences engagement platform for medical affairs, including investigator and patient community engagement. It serves the same biopharma buyers as Comend with a more established, broader product suite.
- BBK Worldwide: BBK Worldwide is a long-established patient recruitment and engagement agency for clinical trials, including rare disease programs. It represents the services-oriented incumbent model competing for the same biopharma marketing budgets.
- Citeline (Pharma Intelligence): Citeline provides drug development intelligence and trial pipeline data to biopharma. While it sells intelligence rather than a marketplace, it is a comparable source of rare disease deal-flow for the same pharma customers Comend targets.
Emerging players
- Mendel (Mendel AI): Mendel uses AI to match patients to clinical trials and structure clinical data. As an emerging player, it overlaps with Comend's goal of accelerating rare disease trial enrollment and translational research.
- Power (Power Life Science): Power is an emerging patient engagement and clinical trial platform with a focus on community and decentralized participation. It targets overlapping biopharma customers and shares Comend's patient-centric design philosophy.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights5 records
Customer concentration
Comend social profiles
Digital presenceComend compliance and trust
Trust signalCompliance1 record
Comend financial estimates
Financial estimateRevenue estimate
Valuation estimate
Comend leadership team
Management profileNumber of profiles
Profiles12 records
Comend funding detail
Funding detailFunding overview
Funding rounds1 record
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Comend M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Comend
What does Comend do?
Comend operates a two-sided SaaS marketplace that lets rare disease patient advocacy groups organize research plans, manage pre-clinical toolkits (biosamples, disease models, clinical datasets), and broadcast Requests for Proposals (RFPs) to researchers, CROs, and service providers. The platform also lets researchers, CROs, biotech, and pharma discover patient groups, research plans, biosamples, disease models, clinical datasets, and RFPs through a unified marketplace. Patient groups access all features for free, while Comend generates revenue by helping biopharma companies identify and evaluate rare disease research opportunities surfaced through the curated ecosystem.
Is Comend a public or private company?
Comend is a private company. It is classified as venture growth investor backed and is currently operating.
When was Comend founded?
Comend was founded in 2023. It employs 1 to 10 people.
Where is Comend based?
Comend is headquartered in Toronto, Canada, in the North America region.
How does Comend make money?
Two revenue lines are on record. Biopharma Partnership Services are the primary driver. The others are platform Services for Patient Groups.
Who are Comend's main competitors?
Direct peers on record are TrialX and Antidote (formerly TrialReach). Broad incumbents are Medable, Veeva Systems, IQVIA, Within3, BBK Worldwide and Citeline (Pharma Intelligence). Emerging players are Mendel (Mendel AI) and Power (Power Life Science).
Does Comend have an API?
Yes. All backend services are guarded by authentication and strict access policies. Protected API endpoints with rate limiting and bot detection. The platform supports social login authentication (Google, Facebook, LinkedIn via OAuth 2.0) and provides user-friendly cookie management controls through CookieYes.
What industry is Comend in?
Comend's product category is Research Collaboration Platform. Its primary akta.pro industry code is HLAGAJAF, Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D), with a secondary code of HLAGAJAM, Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF). Its NAICS code is 5417 and its SIC code is 8731.